BioNTech’s Sean Marett retiring

BioNTech SE (NASDAQ:BNTX) announced the planned retirement of Chief Business and Commercial Officer Sean Marett, and the company’s gradual transfer of his CBO responsibilities to Chief Legal Officer James Ryan, who will become CBO at the end of a transition phase. BioNTech added that Marett will become a specialist adviser, effective July 1, and that it would announce a new chief commercial officer (CCO) by the end of March. Marett joined BioNTech in 2012 and oversaw the business development and product commercialization work that fueled the company’s growth from a small, privately held biotech into a one of the world’s biggest biopharma companies, with a market capitalization of over $21 billion. 

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hired Cristin Hubbard to succeed Jeff Ajer as EVP and CCO, effective May 20. Hubbard was head of global product strategy and global head of diagnostics partnering at Roche (SIX:ROG; OTCQX:RHHBY) and is a veteran of Genentech Inc. Fellow Genentech alum Alexander Hardy is BioMarin’s CEO...